房颤患者CHA2DS2-VASc评分1分的动脉血栓栓塞风险:一项全国性研究
该研究基于丹麦全国登记数据,纳入2000至2021年未接受口服抗凝的房颤患者,按CHA2DS2-VASc评分分组,比较动脉血栓栓塞累积发生率。结果显示CHA2DS2-VASc 1各亚组发生率均高于0分、低于2分(年龄≥75岁),但1分各亚组间无统计学显著差异(P=0.15)。
要点
- CHA2DS2-VASc 1分各亚组动脉血栓栓塞发生率无显著差异(P=0.15)。
- CHA2DS2-VASc 1分各亚组风险均高于0分、低于2分(年龄≥75岁无其他危险因素)。
- 结果支持将CHA2DS2-VASc 1分视为风险相似的中危组。
核心结论
- CHA2DS2-VASc 1分各亚组动脉血栓栓塞发生率均低于年龄≥75岁无其他危险因素的2分患者、高于0分患者。
- CHA2DS2-VASc 1分各亚组间动脉血栓栓塞发生率无统计学显著差异(P=0.15)。
- 研究结果支持当前建议:该中危组患者可被识别为具有相似的动脉血栓栓塞风险。
研究设计与样本
- 链接丹麦国家患者登记和丹麦处方登记,全国性识别2000至2021年未接受口服抗凝的房颤患者。
- 按CHA2DS2-VASc评分分组:0分(男性和女性)、1分(高血压、心衰、糖尿病、血管疾病、年龄65-74岁)、2分(年龄≥75岁无其他危险因素);女性性别不作为任何风险组的危险因素。
- 结局为动脉血栓栓塞(缺血性卒中、肢体栓塞或短暂性脑缺血发作),采用Cox回归分析比较组间差异。
主要发现
- 中位观察1年,CHA2DS2-VASc 0分累积发生率为0.6%(n=154,95%CI 0.6%-0.8%)。
- CHA2DS2-VASc 1分各亚组:心衰1.4%(n=16,95%CI 0.8%-2.2%)、高血压1.9%(n=141,95%CI 1.6%-2.2%)、糖尿病1.7%(n=12,95%CI 0.9%-2.9%)、血管疾病2.0%(n=13,95%CI 1.1%-3.4%)、年龄65-74岁2.3%(n=187,95%CI 2.0%-2.7%)。
- CHA2DS2-VASc 2分(年龄≥75岁无其他危险因素)累积发生率为4.4%(n=533,95%CI 4.1%-4.8%)。
- CHA2DS2-VASc 1分各亚组间差异无统计学意义(P=0.15)。
临床怎么用
- 对于CHA2DS2-VASc 1分房颤患者,可依据当前建议将其视为动脉血栓栓塞风险相似的中危组进行管理。
- 临床决策时无需因1分内不同危险因素(心衰、高血压、糖尿病、血管疾病、年龄65-74岁)而显著区分抗凝策略。
- CHA2DS2-VASc 1分患者风险高于0分但低于年龄≥75岁无其他危险因素者,可据此辅助个体化抗凝讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral anticoagulation is suggested in patients with atrial fibrillation and a CHA2DS2-VASc score ≥1 (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65-74 years, and sex score). To assess granular differences within CHA2DS2-VASc 1, the incidence of arterial thromboembolism according to CHA2DS2-VASc 1 subgroups was examined. METHODS: The Danish National Patient Registry and the Danish Prescription Registry were linked on a nationwide level to identify patients with atrial fibrillation from 2000 to 2021 without oral anticoagulation and categorized according to CHA2DS2-VASc score: CHA2DS2-VASc 0 (male and female subjects); CHA2DS2-VASc 1 (hypertension, heart failure, diabetes, vascular disease, and age 65-74 years); or CHA2DS2-VASc 2 (age ≥75 years without other risk factors). Female sex was not considered a risk factor in any risk group. The outcome was arterial thromboembolism (ischemic stroke, embolism of extremity, or transient cerebral ischemia). Study groups were compared using Cox regression analysis. RESULTS: We included 26 701 patients with a CHA2DS2-VASc 0 score; 22 915 with CHA2DS2-VASc 1 (1483 patients with heart failure, 9066 with hypertension, 843 with diabetes, 770 with vascular disease, and 10 753 who were 65 to 74 years of age); and 14 525 patients with CHA2DS2-VASc 2 (≥75 years of age without other risk factors). With a median of 1 year of observation time, the cumulative incidence of arterial thromboembolism was 0.6% (n=154 [95% CI, 0.6%-0.8%]), 1.4% (n=16 [95% CI, 0.8%-2.2%]), 1.9% (n=141 [95% CI, 1.6%-2.2%]), 1.7% (n=12 [95% CI, 0.9%-2.9%]), 2.0% (n=13 [95% CI, 1.1%-3.4%]), 2.3% (n=187 [95% CI, 2.0%-2.7%]), and 4.4% (n=533 [95% CI, 4.1%-4.8%]) for CHA2DS2-VASc 0, heart failure, hypertension, diabetes, vascular disease, age 65 to 74 years (CHA2DS2-VASc 1), and age ≥75 years (CHA2DS2-VASc 2), respectively. No statistically significant difference was identified among subgroups of CHA2DS2-VASc 1 (P=0.15 for difference). CONCLUSIONS: For patients with atrial fibrillation, all subgroups of CHA2DS2-VASc 1 were associated with lower incidence of arterial thromboembolism compared with age ≥75 years without other risk factors (ie, CHA2DS2-VASc 2) and a higher incidence compared with CHA2DS2-VASc 0. No statistically significant difference was identified between the subgroups of CHA2DS2-VASc 1. These findings support current recommendations that patients within this intermediate risk group could be identified with a similar risk of arterial thromboembolism.
引用
- Østergaard, Olesen, Petersen, et al. Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA2DS2-VASc Score 1: A Nationwide Study. Circulation. 2023. PMID: 38152890. doi:10.1161/CIRCULATIONAHA.123.066477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。